Description

Verteporfin is a potent photosensitizer belonging to the benzoporphyrin derivative class, widely recognized for its pivotal role in photodynamic therapy (PDT). Its primary commercial value lies in its ability to generate cytotoxic singlet oxygen upon activation with non-thermal red light, enabling precise, localized treatment of aberrant tissues. This makes it a critical active pharmaceutical ingredient (API) for manufacturers in the ophthalmic and oncological sectors, particularly for the treatment of age-related macular degeneration (AMD) and certain neoplastic conditions. The compound is supplied under stringent quality controls to ensure efficacy and safety in final drug formulations.

Application

• Ophthalmic Pharmaceuticals: As the key API in Visudyne® and generic equivalents for the photodynamic treatment of predominantly classic subfoveal choroidal neovascularization due to AMD, pathologic myopia, or presumed ocular histoplasmosis.
• Oncological Research & Therapeutics: Investigated for use in PDT for various solid tumors, including skin, pancreatic, and prostate cancers, leveraging its selective localization and activation.
• Preclinical Research: Utilized in laboratory studies to model PDT mechanisms, study vascular-targeted therapies, and develop new light-activated treatment modalities.
• Pharmaceutical Development: Serves as a reference standard and starting material for the synthesis and quality control of verteporfin-based injectable formulations.
• Biochemical Research: Used as a tool compound to induce controlled oxidative stress and study cellular apoptosis pathways in vitro.

Basic Information

Product Name	Verteporfin
CAS No.	129497-78-5
Molecular Formula	C41H42N4O8
Molecular Weight	718.80 g/mol
Synonyms	Benzoporphyrin derivative monoacid ring A (BPD-MA); Visudyne; CL 318952; BPD-MA; 9-Methyl-14-oxo-4,8,13,18-tetramethyl-20-oxo-3-(1-oxo-2-propen-1-yl)-3-vinyl-2-aza-21-carbabicyclo[16.3.1]docosa-1(21),4,6,8,13,15,17,19-octaen-22-oate; LS-2616; Verteporphin.
EINECS	Contact for details

Quality Control

Our Verteporfin is manufactured and tested to meet the exacting standards required for pharmaceutical active ingredients. Quality assurance protocols include stringent identity, purity, and impurity profile testing, typically aligned with pharmacopeial expectations. A comprehensive Certificate of Analysis (COA) is provided with each batch, detailing results for key parameters such as assay, related substances, residual solvents, and specific tests for photosensitizer activity. We support compliance with cGMP, ICH Q7, and other relevant regulatory frameworks for global supply.

Storage

Preserve in a tightly closed container, protected from light. This product is strictly light-sensitive and must be protected from all light exposure during storage and handling to prevent degradation. Store at controlled room temperature, typically between 15°C and 25°C, in a dry environment. The container should be kept in the original outer packaging until use.

Specification

Item	Specification
Appearance	Dark green to blackish green solid
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0% (anhydrous basis)
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Water Content (KF)	≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.